Vicore Pharma Holding AB is a drug development company. The company's through is a subsidiary is developing a new type of pharmaceutical compound, known as AT2R agonists, to stimulate the AT2 receptor within the Renin-Angiotensin system. Its drug candidate, C21, is the first small molecule compound in its class.Vicore Pharma Holding AB is a drug development company. The company's through is subsdiary is developing a new type of pharmaceutical compound, known as AT2R agonists, to stimulate the AT2 receptor within the Renin-Angiotensin systemet.